{
    "code": "02025647",
    "url": "https:\/\/www.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=02025647",
    "time": "2018-01-19 03:27:35",
    "許可證字號": "衛署藥輸字第025647號",
    "註銷狀態": "",
    "註銷日期": "",
    "註銷理由": "",
    "有效日期": "111\/03\/08",
    "發證日期": "101\/03\/08",
    "許可證種類": "製　劑",
    "舊證字號": "",
    "醫療器材級數": "",
    "通關簽審文件編號": "DHA00202564702",
    "中文品名": "拜瑞妥膜衣錠20毫克",
    "英文品名": "Xarelto Film-coated Tablets 20 mg",
    "適應症": "1. 用於非瓣膜性心房顫動(non-valvular atrial fibrillation)且有下列至少一項危險因子者成人病患，預防中風及全身性栓塞(systemic embolism)。危險因子例如：心衰竭、高血壓、年齡大於等於75歲、糖尿病、曾發生腦中風或短暫性腦缺血發作(transient ischemic attack)。\r\n2. Rivaroxaban用於靜脈血栓高危險群(曾發生有症狀之靜脈血栓症)病患，以預防其於接受下肢重大骨科手術後之靜脈血栓栓塞症(VTE)。\r\n3. 治療深部靜脈血栓與肺栓塞及預防再發性深部靜脈血栓與肺栓塞。\r\n說明：各適應症之用法用量，請參閱「用法用量」欄。",
    "劑型": "116膜衣錠",
    "包裝": "2-1000錠鋁箔盒裝",
    "標籤、仿單及包裝加註": "",
    "藥品類別": "06須由醫師處方使用",
    "主成分略述": [
        "RIVAROXABAN"
    ],
    "限制項目": "",
    "申請商名稱": "1426201100  臺灣拜耳股份有限公司",
    "主製造廠": {
        "主製造廠": "",
        "製造廠名稱": "F479012000  BAYER PHARMA AG",
        "製造廠廠址": "D-51368 LEVERKUSEN, GERMANY",
        "製造廠公司地址": ""
    },
    "CCC號列": "",
    "藥理治療分類": "",
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "9200099500",
            "成分名稱": "RIVAROXABAN",
            "含量描述": "",
            "含量": "20.0000000000",
            "單位": "MG"
        }
    ],
    "仿單外盒": [
        {
            "title": "03_Xarelto依核定草本印妥之中文仿單PDF電子檔-106-11-16.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02025647&Seq=008&Type=9"
        },
        {
            "title": "Xarelto 20mg_025647_box_正-104-12-31(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02025647&Seq=004&Type=8"
        }
    ]
}